| Old Articles: <Older 16031-16040 Newer> |
|---|
 |
The Motley Fool
August 3, 2006
Stephen D. Simpson |
Still Time to Tie Into Tyco The conglomerate's stock is undervalued, but also underperforming. Investors, take note.   |
The Motley Fool
August 3, 2006
Selena Maranjian |
News Flash: The Market Is Down! On days or months when the market has taken a beating, remember that can mean there are special opportunities out there. What looks like bad news can actually be good news for you. |
The Motley Fool
August 3, 2006
Stephen D. Simpson |
XL Remains on the Road to Recovery This balanced insurance play seems to be getting its act together. Turnarounds are tricky in general, often requiring investors obtain a better-than-average appreciation and understanding of the industry. |
The Motley Fool
August 3, 2006
Jeff Hwang |
Gaming Roundup: WYNN, LVS Q2 Earnings Review Expenses and lower-than-normal hold percentages in Las Vegas led to disappointing second-quarter results from Wynn Resorts and Las Vegas Sands. Investors, take note. |
The Motley Fool
August 3, 2006
Robert Brokamp |
Pave the Road to Retirement With Dividends Dividend-paying stocks are a great way to build your nest egg. |
The Motley Fool
August 3, 2006
Stephen D. Simpson |
ABB's Got Gear for the Grid Demand from power companies should fuel this infrastructure firm's future growth. Investors, is it time to buy? |
The Motley Fool
August 3, 2006
Seth Jayson |
Cadbury: Not Sweet Enough Good company, so-so price. In the international beverage biz, there are better deals out there, as well as better confection plays. Investors, take note. |
The Motley Fool
August 3, 2006
Rick Aristotle Munarriz |
LeapFrog Stinks at Frogger The educational toy specialist flunks out in the second quarter. Thankfully, LeapFrog has the time to get it right, since its cash-rich balance sheet sports nearly $3 a share in greenbacks. Investors will have to be patient. |
The Motley Fool
August 3, 2006
S.J. Caplan |
Steris Still a Middling Student Beating expectations by a penny doesn't win the manufacturer of infection control and prevention products any high marks. Investors, take note. |
The Motley Fool
August 3, 2006
S.J. Caplan |
AstraZeneca's Path to Avoid Pain The pharmaceutical giant partners with Pozen to co-develop a drug. Take heart, AstraZeneca shareholders! No queasy stomachs are expected in your future. |
| <Older 16031-16040 Newer> Return to current articles. |
